Glaucoma - 5EU Drug Forecast and Market Analysis to 2023
BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com
Glaucoma - 5EU Drug Forecast and Market Analysis to 2023

Summary

Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie’s Rhopressa, Bausch & Lomb’s Vesneo (latanoprost bunod), and Inotek’s trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market.

GlobalData estimates that drug sales for glaucoma in the 5EU reached $250m during the base year of 2013. After an initial period of minimal growth, GlobalData anticipates a moderate and steady growth trend from 2015 onwards. This can be partially attributed to the expected arrival of the recently approved FDC products Simbrinza and Taptiqom during 2015, and to the expected launch of five pipeline products during the forecast period.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of Glaucoma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Glaucoma market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Glaucoma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.

Additional Details

Publisher: Global Data
Reference: GDHC321CFR
Number of Pages: 245
Report Format: PDF
Publisher Information:
Table Of Contents for Glaucoma - 5EU Drug Forecast and Market Analysis to 2023

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Symptoms
3.4 Diagnosis
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines
4.1.3 Leading Prescribed Drugs
4.1.4 Clinical Practice
4.2 5EU
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Main Brands and Drug Classes
5.2.1 Xalatan (latanoprost)
5.2.2 Lumigan (bimatoprost)
5.2.3 Travatan (travoprost)
5.2.4 Tapros (tafluprost)
5.2.5 Beta Blockers
5.2.6 Carbonic Anhydrase Inhibitors
5.2.7 Alpha-Adrenergic Agonists
5.2.8 Simbrinza (brinzolamide + brimonidine)
5.2.9 Glanatec (ripasudil hydrochloride hydrate)
6 Unmet Need and Opportunity
6.1 Overview
6.2 Simplified Dosing Regimen
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Reminder Systems
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Long-Acting Therapy
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 New Classes of IOP-Lowering Drugs
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Neuroprotective Drugs
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Improved Diagnosis and Monitoring
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trials
7.2.1 Clinical Trial Mapping
7.2.2 Clinical Trial Design
7.3 Promising Drugs in Clinical Development
7.3.1 Rhopressa
7.3.2 Roclatan
7.3.3 Vesneo
7.3.4 Bimatoprost SR
7.3.5 Trabodenoson
7.3.6 ROCK Inhibitor AMA-0076
7.3.7 DE-117
7.3.8 OXT-TP
7.4 Promising Drugs in Early-Stage Development
7.4.1 Sustained-Release PGA Products
7.5 Other Drugs in Development
8 Market Outlook
8.1 5EU
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Percent Drug-Treated Patients
9.4.2 Drugs Included in Each Therapeutic Class
9.4.3 Launch and Patent Expiry Dates
9.4.4 General Pricing Assumptions
9.4.5 Individual Drug Assumptions
9.4.6 Pricing of Pipeline Agents
9.5 Primary Research - KOLs Interviewed for this Report
9.6 Primary Research - High-prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Epidemiologist
9.7.4 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer
List Of Tables in Glaucoma - 5EU Drug Forecast and Market Analysis to 2023

1.1 List of Tables

Table 1: Symptoms of Glaucoma 22
Table 2: Diagnostic Tests for Glaucoma 22
Table 3: National and International Treatment Guidelines for Glaucoma 29
Table 4: Most Prescribed Drugs for Glaucoma in the Global Markets, 2013 30
Table 5: Country Profile - 5EU 37
Table 6: Leading Treatments for Glaucoma, 2013 39
Table 7: Product Profile - Xalatan 43
Table 8: Xalatan SWOT Analysis, 2014 44
Table 9: Global Sales Forecast ($m) for Xalatan, 2013-2023 45
Table 10: Global Sales Forecast ($m) for Generic Latanoprost, 2013-2023 45
Table 11: Product Profile - Lumigan 48
Table 12: Lumigan SWOT Analysis, 2014 49
Table 13: Global Sales Forecast ($m) for Lumigan, 2013-2023 50
Table 14: Product Profile - Travatan 52
Table 15: Travatan SWOT Analysis, 2014 53
Table 16: Global Sales Forecast ($m) for Travatan/Travatan Z, 2013-2023 54
Table 17: Global Overview of Tafluprost 54
Table 18: Product Profile - Tapros Franchise 57
Table 19: Tafluprost Adverse Events 59
Table 20: Tafluprost SWOT Analysis, 2014 59
Table 21: Global Sales Forecast ($m) for the Tapros Franchise, 2013-2023 60
Table 22: Beta Blockers Available in the 7MM 63
Table 23: Global Sales Forecast ($m) for Beta Blocker Drugs, 2013-2023 66
Table 24: Carbonic Anhydrase Inhibitors Available in the 7MM 67
Table 25: Global Sales Forecast ($m) for Carbonic Anhydrase Inhibitor Drugs, 2013-2023 70
Table 26: Alpha-Adrenergic Agonists available in the 7MM 71
Table 27: Global Sales Forecast ($m) for Alpha-Adrenergic Agonist Drugs, 2013-2023 73
Table 28: Product Profile - Simbrinza 74
Table 29: Simbrinza SWOT Analysis, 2014 75
Table 30: Global Sales Forecast ($m) for Simbrinza, 2013-2023 76
Table 31: Product Profile - Glanatec 79
Table 32: Glanatec SWOT Analysis, 2014 81
Table 33: Global Sales Forecast ($m) for Glanatec, 2013-2023 81
Table 34: Unmet Needs and Opportunities in Glaucoma 85
Table 35: Promising Drugs in Clinical Development for Glaucoma 111
Table 36: Comparison of Drugs in Development for Glaucoma, 2014 112
Table 37: Product Profile - Rhopressa 121
Table 38: SWOT Analysis - Rhopressa, 2014 124
Table 39: Global Sales Forecasts ($m) for Rhopressa, 2013-2023 125
Table 40: Product Profile - Roclatan 129
Table 41: SWOT Analysis - Roclatan, 2014 132
Table 42: Global Sales Forecasts ($m) for Roclatan, 2013-2023 133
Table 43: Product Profile - Vesneo 138
Table 44: SWOT Analysis - Vesneo, 2014 141
Table 45: Global Sales Forecasts ($m) for Vesneo, 2013-2023 142
Table 46: Product Profile - Bimatoprost SR 147
Table 47: SWOT Analysis - Bimatoprost SR, 2014 149
Table 48: Global Sales Forecasts ($m) for Bimatoprost SR, 2013-2023 150
Table 49: Product Profile - Trabodenosen 154
Table 50: SWOT Analysis - Trabodenosen, 2014 157
Table 51: Global Sales Forecasts ($m) for Trabodenosen, 2013-2023 158
Table 52: Product Profile - OPC-1085EL 159
Table 53: SWOT Analysis - OPC-1085EL, 2014 161
Table 54: Global Sales Forecasts ($m) for OPC-1085EL, 2013-2023 162
Table 55: Product Profile - DE-117 164
Table 56: SWOT Analysis - DE-117, 2014 165
Table 57: Product Profile - OXT-TP 166
Table 58: SWOT Analysis - OTX-TP, 2014 167
Table 59: Drugs in Development, 2014 171
Table 60: 5EU Sales Forecast ($m) for Glaucoma, 2013-2023 175
Table 61 Key Events Impacting Sales for Glaucoma in the 5EU, 2013-2023 178
Table 62: Glaucoma Market - Drivers and Barriers in the 5EU, 2013-2023 179
Table 63: Key Launch Dates 228
Table 64: Key Patent Expiries 228
Table 65: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 241
List Of Figures, Charts and Diagrams in Glaucoma - 5EU Drug Forecast and Market Analysis to 2023

1.2 List of Figures

Figure 1: Open and Closed Iridocorneal Angles 13
Figure 2: The Aqueous Humor Cycle 16
Figure 3: Optic Nerve Damage - Cupping 18
Figure 4: Comparison of Healthy and Glaucomous Optic Nerves 26
Figure 5: Glaucoma Clinical Treatment Flowchart 32
Figure 6: Glaucoma - Number of Phase II and III/IIb Clinical Trials in Various Drug Classes in the 7MM 110
Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in Glaucoma, 2013-2023 113
Figure 8: Rhopressa’s Development in Glaucoma 121
Figure 9: Clinical and Commercial Positioning of Rhopressa 123
Figure 10: Roclatan’s Development in Glaucoma 130
Figure 11: Clinical and Commercial Positioning of Roclatan 131
Figure 12: Vesneo Development in Glaucoma 138
Figure 13: Clinical and Commercial Positioning of Vesneo 140
Figure 14: Clinical and Commercial Positioning of Bimatoprost SR 148
Figure 15: Trabodenoson’s Development in Glaucoma 154
Figure 16: Clinical and Commercial Positioning of Trabodenosen 156
Figure 17: OPC-1085EL’s Development in Glaucoma 160
Figure 18: Clinical and Commercial Positioning of OPC-1085EL 161
Figure 19: DE-117’s Development in Glaucoma 164
Figure 20: Drug Sales by Class for Glaucoma in the 5EU, 2013-2023 176
Figure 21: Drug Sales by Country for Glaucoma in the 5EU, 2013-2023 177
How to Buy...

Glaucoma - 5EU Drug Forecast and Market Analysis to 2023

**Option 1 - Online**
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/19813

**Option 2 - Request a Proforma Invoice**
Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com
or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

- **Your Name:**
- **Job Title:**
- **Your Email:**
- **Your Contact Phone:**
- **Company Name:**
- **Address:**
- **Post/Zip Code:**
- **Country:**
- **P.O. Number:**
- **Any Other Instructions:**

**Pricing Options:** (please tick one)
- **$6995** | Single User Price
- **$13990** | Site License Price
- **$20985** | Enterprise License Price

**Payment Options:** (please tick one)
- **Online Credit Card** (we will email you the invoice with a payment link)
- **Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:**

**Option 3 - Phone Us on +44 (0)1300 321501**
We will be delighted to give you our personal attention.